Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Min XiongXuliren WangDouwaner LiuBingqiu XiuQi ZhangWeiru ChiChih Wan GohLiyi ZhangMing ChenHengyu RenZhi-Ming ShaoBenlong YangJiong WuPublished in: Cancer medicine (2024)
The genetic mutation profiles of Chinese HER2+ patients who received NAT were discrepant with respect to HR status or DFS events. TP53 mutations have significant prognostic value in patients with NAT for HER2-positive BC and patients benefit differently depending on HR status, the neoadjuvant regimen and response, which highlights the significance of genetic factors in treatment customization based on individual genetic and clinical characteristics.
Keyphrases
- patients undergoing
- copy number
- rectal cancer
- genome wide
- end stage renal disease
- lymph node
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- squamous cell carcinoma
- peritoneal dialysis
- stem cells
- gene expression
- radiation therapy
- patient reported outcomes
- patient reported
- combination therapy